Cambridge, Mass.-based Hydra Biosciences inked its second partnership with Boehringer Ingelheim in as many years. The partners announced 13 April that they have entered into a research collaboration to identify transient receptor potential (TRP) inhibitors for the treatment of renal diseases. Hydra received an undisclosed upfront payment and is eligible to receive research funding, milestone payments and tiered royalties on any products that result. The tie-up comes exactly a year after the pair inked their first partnership in which they agreed to develop small molecule TRPC4/5 inhibitors for central nervous system diseases and disorders. Hydra received an upfront payment and research funding with the potential to earn additional milestone fees and royalties.
Hydra teams up with BI again
More from Archive
More from Scrip
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.